Upstream Bio Inc. (UPB)
| Bid | 7.89 |
| Market Cap | 396.88M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.36 |
| PE Ratio (ttm) | -5.44 |
| Forward PE | -4.15 |
| Analyst | Buy |
| Ask | 7.91 |
| Volume | 171,046 |
| Avg. Volume (20D) | 328,939 |
| Open | 7.96 |
| Previous Close | 7.93 |
| Day's Range | 7.23 - 7.98 |
| 52-Week Range | 6.65 - 29.46 |
| Beta | 1.12 |
About UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in ...
Analyst Forecast
According to 4 analyst ratings, the average rating for UPB stock is "Buy." The 12-month stock price forecast is $56.5, which is an increase of 663.00% from the latest price.
2 months ago · seekingalpha.com
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting DifferentiationUpstream Bio, Inc. raised approximately $293 million in an IPO, positioning it to leverage upstream pathway targeting of TSLP for treatment of patients with respiratory disorders using verekitug. Rele...